These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 14567797)

  • 41. Expression and purification of human vascular-endothelial-growth-factor-receptor-2 tyrosine kinase in Streptomyces for inhibitor screening.
    Liu C; Guo L; Yao C; Zhang R; Li Y
    Biotechnol Appl Biochem; 2008 Jun; 50(Pt 2):113-9. PubMed ID: 17824843
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
    Haspel HC; Scicli GM; McMahon G; Scicli AG
    Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Readout technologies for highly miniaturized kinase assays applicable to high-throughput screening in a 1536-well format.
    Klumpp M; Boettcher A; Becker D; Meder G; Blank J; Leder L; Forstner M; Ottl J; Mayr LM
    J Biomol Screen; 2006 Sep; 11(6):617-33. PubMed ID: 16760365
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Development, validation and implementation of immobilized metal affinity for phosphochemicals (IMAP)-based high-throughput screening assays for low-molecular-weight compound libraries.
    Sharlow ER; Leimgruber S; Yellow-Duke A; Barrett R; Wang QJ; Lazo JS
    Nat Protoc; 2008; 3(8):1350-63. PubMed ID: 18714303
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vascular endothelial growth factor receptors: molecular mechanisms of activation and therapeutic potentials.
    Rahimi N
    Exp Eye Res; 2006 Nov; 83(5):1005-16. PubMed ID: 16713597
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A time-resolved fluorescence resonance energy transfer assay for high-throughput screening of 14-3-3 protein-protein interaction inhibitors.
    Du Y; Fu RW; Lou B; Zhao J; Qui M; Khuri FR; Fu H
    Assay Drug Dev Technol; 2013 Jul; 11(6):367-81. PubMed ID: 23906346
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Homogeneous single-label tyrosine kinase activity assay for high throughput screening.
    Tong-Ochoa N; Kopra K; Syrjänpää M; Legrand N; Härmä H
    Anal Chim Acta; 2015 Oct; 897():96-101. PubMed ID: 26515010
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Potent inhibition of angiogenesis by D,L-peptides derived from vascular endothelial growth factor receptor 2.
    Piossek C; Thierauch KH; Schneider-Mergener J; Volkmer-Engert R; Bachmann MF; Korff T; Augustin HG; Germeroth L
    Thromb Haemost; 2003 Sep; 90(3):501-10. PubMed ID: 12958620
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Multiplexing terbium- and europium-based TR-FRET readouts to increase kinase assay capacity.
    Horton RA; Vogel KW
    J Biomol Screen; 2010 Sep; 15(8):1008-15. PubMed ID: 20460248
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fluorescent resonance energy transfer imaging of VEGFR dimerization.
    Ahmadova Z; Yagublu V; Förg T; Hajiyeva Y; Jesenofsky R; Hafner M; Keese M
    Anticancer Res; 2014 May; 34(5):2123-33. PubMed ID: 24778014
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Current in vitro kinase assay technologies: the quest for a universal format.
    Jia Y; Quinn CM; Kwak S; Talanian RV
    Curr Drug Discov Technol; 2008 Mar; 5(1):59-69. PubMed ID: 18537568
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Homogeneous time-resolved fluorescence and its applications for kinase assays in drug discovery.
    Jia Y; Quinn CM; Gagnon AI; Talanian R
    Anal Biochem; 2006 Sep; 356(2):273-81. PubMed ID: 16814737
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Using TR-FRET to Investigate Protein-Protein Interactions: A Case Study of PXR-Coregulator Interaction.
    Lin W; Chen T
    Adv Protein Chem Struct Biol; 2018; 110():31-63. PubMed ID: 29412999
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biotinylated peptides for rapid identification of substrates and inhibitors of kinases and phosphatases with fluorescence superquenching.
    Wittenburg S; Stankewicz C; Rininsland F
    Assay Drug Dev Technol; 2006 Oct; 4(5):535-43. PubMed ID: 17115924
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A directly labeled TR-FRET assay for monitoring phosphoinositide-3-kinase activity.
    Yang X; Li P; Feldberg L; Kim SC; Bowman M; Hollander I; Mallon R; Wolf SF
    Comb Chem High Throughput Screen; 2006 Aug; 9(7):565-70. PubMed ID: 16925516
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluating PI3 kinase isoforms using Transcreener ADP assays.
    Klink TA; Kleman-Leyer KM; Kopp A; Westermeyer TA; Lowery RG
    J Biomol Screen; 2008 Jul; 13(6):476-85. PubMed ID: 18566477
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A High-Throughput Method for Measuring Drug Residence Time Using the Transcreener ADP Assay.
    Kumar M; Lowery RG
    SLAS Discov; 2017 Aug; 22(7):915-922. PubMed ID: 28346107
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of assay technologies for a tyrosine kinase assay generates different results in high throughput screening.
    Sills MA; Weiss D; Pham Q; Schweitzer R; Wu X; Wu JJ
    J Biomol Screen; 2002 Jun; 7(3):191-214. PubMed ID: 12097183
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Salicylates are interference compounds in TR-FRET assays.
    Hanley RP; Horvath S; An J; Hof F; Wulff JE
    Bioorg Med Chem Lett; 2016 Feb; 26(3):973-977. PubMed ID: 26733476
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Optimization and validation of a DYRK1A TR-FRET assay for high-throughput screening.
    Tarpley M; Caligan TB; Onyenwoke RU; Williams KP
    MethodsX; 2021; 8():101383. PubMed ID: 34430279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.